Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers (Q35577983)

9 August 2017

title

Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers (English)

1 reference

9 August 2017

0 references

cervix uterine cancer

1 reference

Rebecca R. Richards-Kortum

inferred from title

author

object named as

Rebecca Richards-Kortum

9

0 references

Michele Follen

1

object named as

Michele Follen

1 reference

9 August 2017

Frank L. Meyskens, Jr.

2

object named as

Frank L Meyskens

1 reference

9 August 2017

7

Jagannadha Sastry

1 reference

9 August 2017

Ronald D Alvarez

3

1 reference

9 August 2017

Joan L Walker

4

1 reference

9 August 2017

Maria C Bell

5

1 reference

9 August 2017

Karen Adler Storthz

6

1 reference

9 August 2017

Krishnendu Roy

8

1 reference

9 August 2017

Terri L Cornelison

10

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

98

1 reference

9 August 2017

issue

9 Suppl

1 reference

9 August 2017

page(s)

2044-2051

1 reference

Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

Papillomaviruses and cervical cancer: pathogenesis and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

The 2001 Bethesda System: terminology for reporting results of cervical cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Chemoprevention trials and surrogate end point biomarkers in the cervix

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Why phase II trials in cervical chemoprevention are negative: what have we learned?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Chemoprevention of cervix cancer: Phase I-II: A feasibility study involving the topical vaginal administration of retinyl acetate gel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Plasma reduced and total ascorbic acid in human uterine cervix dysplasias and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

The effect of beta-carotene on the regression and progression of cervical dysplasia: a clinical experiment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

A randomized clinical trial of beta carotene vs placebo for the treatment of cervical HPV infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Folate deficiency and cervical dysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Therapeutic vaccines for human papillomaviruses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Efficacy of preventive human papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Prevention of cervical cancer with vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11674

7 January 2021

Identifiers

DOI

10.1002/CNCR.11674

1 reference

9 August 2017

1 reference